; (E) submit an annual report to the Secretary and Congress on the creation and implementation of the national strategic plan under subparagraph (A); and (F) ensure the inclusion of men at high risk for prostate cancer, including men from ethnic and racial populations and men who are least likely to receive care, in clinical, research, and service efforts, with the purpose of decreasing health disparities. (3) Membership (A) Federal members The Council shall be led by the Secretary or designee and comprised of the following experts: (i) Two representatives of the National Institutes of Health, including 1 representative of the National Institute of Biomedical Imaging and Bioengineering and 1 representative of the National Cancer Institute. (ii) A representative of the Centers for Disease Control and Prevention. (iii) A representative of the Centers for Medicare & Medicaid Services. (iv) A designee of the Director of the Department of Defense Congressionally Directed Medical Research Program. (v) A designee of the Director of the Office of Minority Health. (vi) A representative of the Food and Drug Administration. (vii) A representative of the Agency for Healthcare Research and Quality. (B) Non-federal members In addition to the members described in subparagraph (A), the Council shall include 14 expert members from outside the Federal Government, which shall include— (i) 6 prostate cancer patient advocates, including— (I) 2 patient-survivors; (II) 2 caregivers of prostate cancer patients; and (III) 2 representatives from national prostate cancer disease organizations that fund research or have demonstrated experience in providing assistance to patients, families, and medical professionals, including information on health care options, education, and referral